Regulation of [3H]dopamine release from guinea pig striatum by NMDA receptor/channel activators and inhibitors. 1990

L L Werling, and H M Jacocks, and P N McMahon
Department of Pharmacology, Uniformed Services University, Bethesda, Maryland.

Excitatory amino acids, that interact with the N-methyl-D-aspartate (NMDA) receptor stimulate release of [3H]dopamine [3H]DA) from the striatum of the guinea pig and rat in a concentration-dependent manner. DA release was measured in the presence of domperidone and nomifensine to avoid complications associated with autoreceptor alteration of and reuptake of released DA. This release is inhibited by magnesium. Therefore, all experiments were performed in the absence of this ion. The competitive NMDA antagonists D-(-)2-amino-5-phosphonopentanoic acid and 3-[(+-)-2-carboxypiperazin-4-yl]-propyl-1-phosphonic acid and the noncompetitive antagonists (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine and phencyclidine also inhibit NMDA-stimulated release. Glycine enhances NMDA-stimulated release and can release [3H]DA in the absence of added NMDA. Release stimulated by glycine alone is not affected by 3-[(+-)-2-carboxypiperazine-4-yl]-propyl-1-phosphonic acid. Conversely, if the glycine antagonist 3-amino-1-hydroxy-2-pyrrolidone or 6-cyano-7-nitroquinoxaline-2,3-dione is included, NMDA elicits less release of [3H]DA. This inhibition can be overcome by increasing the concentration of glycine. The kappa-selective opioid agonist trans-(+-)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl) cyclohexyl]-benzene-acetamide is also capable of inhibiting the NMDA-stimulated release of [3H]DA from guinea pig and rat striatum.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007473 Ion Channels Gated, ion-selective glycoproteins that traverse membranes. The stimulus for ION CHANNEL GATING can be due to a variety of stimuli such as LIGANDS, a TRANSMEMBRANE POTENTIAL DIFFERENCE, mechanical deformation or through INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS. Membrane Channels,Ion Channel,Ionic Channel,Ionic Channels,Membrane Channel,Channel, Ion,Channel, Ionic,Channel, Membrane,Channels, Ion,Channels, Ionic,Channels, Membrane
D008274 Magnesium A metallic element that has the atomic symbol Mg, atomic number 12, and atomic weight 24.31. It is important for the activity of many enzymes, especially those involved in OXIDATIVE PHOSPHORYLATION.
D008297 Male Males
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011759 Pyrrolidines Compounds also known as tetrahydropyridines with general molecular formula (CH2)4NH. Tetrahydropyridine,Tetrahydropyridines
D011810 Quinoxalines Quinoxaline
D011957 Receptors, Opioid Cell membrane proteins that bind opioids and trigger intracellular changes which influence the behavior of cells. The endogenous ligands for opioid receptors in mammals include three families of peptides, the enkephalins, endorphins, and dynorphins. The receptor classes include mu, delta, and kappa receptors. Sigma receptors bind several psychoactive substances, including certain opioids, but their endogenous ligands are not known. Endorphin Receptors,Enkephalin Receptors,Narcotic Receptors,Opioid Receptors,Receptors, Endorphin,Receptors, Enkephalin,Receptors, Narcotic,Receptors, Opiate,Endorphin Receptor,Enkephalin Receptor,Normorphine Receptors,Opiate Receptor,Opiate Receptors,Opioid Receptor,Receptors, Normorphine,Receptors, beta-Endorphin,beta-Endorphin Receptor,Receptor, Endorphin,Receptor, Enkephalin,Receptor, Opiate,Receptor, Opioid,Receptor, beta-Endorphin,Receptors, beta Endorphin,beta Endorphin Receptor,beta-Endorphin Receptors
D003342 Corpus Striatum Striped GRAY MATTER and WHITE MATTER consisting of the NEOSTRIATUM and paleostriatum (GLOBUS PALLIDUS). It is located in front of and lateral to the THALAMUS in each cerebral hemisphere. The gray substance is made up of the CAUDATE NUCLEUS and the lentiform nucleus (the latter consisting of the GLOBUS PALLIDUS and PUTAMEN). The WHITE MATTER is the INTERNAL CAPSULE. Lenticular Nucleus,Lentiform Nucleus,Lentiform Nuclei,Nucleus Lentiformis,Lentiformis, Nucleus,Nuclei, Lentiform,Nucleus, Lenticular,Nucleus, Lentiform,Striatum, Corpus
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D005998 Glycine A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. Aminoacetic Acid,Glycine, Monopotassium Salt,Glycine Carbonate (1:1), Monosodium Salt,Glycine Carbonate (2:1), Monolithium Salt,Glycine Carbonate (2:1), Monopotassium Salt,Glycine Carbonate (2:1), Monosodium Salt,Glycine Hydrochloride,Glycine Hydrochloride (2:1),Glycine Phosphate,Glycine Phosphate (1:1),Glycine Sulfate (3:1),Glycine, Calcium Salt,Glycine, Calcium Salt (2:1),Glycine, Cobalt Salt,Glycine, Copper Salt,Glycine, Monoammonium Salt,Glycine, Monosodium Salt,Glycine, Sodium Hydrogen Carbonate,Acid, Aminoacetic,Calcium Salt Glycine,Cobalt Salt Glycine,Copper Salt Glycine,Hydrochloride, Glycine,Monoammonium Salt Glycine,Monopotassium Salt Glycine,Monosodium Salt Glycine,Phosphate, Glycine,Salt Glycine, Monoammonium,Salt Glycine, Monopotassium,Salt Glycine, Monosodium

Related Publications

L L Werling, and H M Jacocks, and P N McMahon
September 1985, The Journal of pharmacology and experimental therapeutics,
L L Werling, and H M Jacocks, and P N McMahon
October 1997, Naunyn-Schmiedeberg's archives of pharmacology,
L L Werling, and H M Jacocks, and P N McMahon
July 1996, Schizophrenia research,
L L Werling, and H M Jacocks, and P N McMahon
July 1988, The Journal of pharmacology and experimental therapeutics,
L L Werling, and H M Jacocks, and P N McMahon
May 1997, European journal of pharmacology,
L L Werling, and H M Jacocks, and P N McMahon
September 2001, Current drug targets,
L L Werling, and H M Jacocks, and P N McMahon
September 1992, Journal of neurochemistry,
L L Werling, and H M Jacocks, and P N McMahon
December 1988, The American journal of physiology,
Copied contents to your clipboard!